Item 3.02. Unregistered Sales of Equity Securities.
On March 6, 2024 and March 7, 2024, the holder of pre-funded warrants to purchase 1/19th of a share of common stock of 180 Life Sciences Corp. (the "Company", "we" and "us"), at an exercise price of $0.0019 per share, exercised 1,368,000 and 1,178,000 warrants, respectively, for an aggregate of $254.60 of cash. As a result of the exercises, the holder was issued 72,000 and 62,000 shares of common stock, respectively (after adjusting for the Company's 1-for-19 reverse stock split which was effective on February 28, 2024, as disclosed in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on February 28, 2024 (the "Prior Form 8-K")). The exercise of the warrants was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The resale of the shares of common stock issuable upon exercise of the warrants was registered under a registration statement declared effective under the Securities Act.
After the issuances described above, the Company will have approximately 852,758 shares of common stock issued and outstanding; and no pre-funded warrants remain outstanding.
Attachments
Disclaimer
180 Life Sciences Corp. published this content on 08 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 March 2024 21:59:53 UTC.